ArticleCancer medicine2025
De Novo EGFR -ALK and EGFR -ROS1 Co-Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Real-World Evaluation of Next-Generation Sequencing in Lung Cancer: Associations Between Histological Subtypes and Genomic Alterations.Current issues in molecular biology · 2026Article
- [Clinicopathological Characteristics of ROS1-positive Non-small Cell Lung Cancer Based on Next-generation Sequencing].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Article
- De Novo EGFR -ALK and EGFR -ROS1 Co-Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDe novo epidermal growth factor receptor-anaplastic lymphoma kinase (EGFR-ALK) and EGFR-ROS proto-oncogene 1 (EGFR-ROS1) co-mutations in non-small-cell lung cancer (NSCLC), conditions traditionally considered mutually exclusive. We present the first large‑scale analysis of their clinical and genomic profiles.
methodsWe identified 26 patients with EGFR-ALK (n = 20) or EGFR-ROS1 (n = 6) co-mutations from two institutions and compared them with cohorts of EGFR-only, ALK-only, ROS1-only, and non-co-mutated (NC) controls. Additionally, we validated findings in 66 published co-mutation cases through a literature review (2010-2023).
resultsThe co-mutation frequencies were 0.36% for EGFR-ALK and 0.11% for EGFR-ROS1. EGFR-ALKco-mutations were more commonly diagnosed at earlier stages (50.0% stage 0-II vs. 22.6% in ALK-only, p = 0.03). Patients with EGFR-ALK co-mutations were older than those with ALK-only mutations (≥ 60 years: 60.0% vs. 24.5% in ALK-only, p = 0.01), a trend validated in external pooled cases (51.9% vs. 24.5%, p = 0.01). All EGFR-ROS1cases were never-smokers and predominantly female (66.7%), a trend consistent with external pooled cases. Co-mutated tumors were enriched for EGFR exon 19 deletion (19del, 60.0% vs. 42.2% EGFR-only) and depleted for L858R. Additionally, 80.0% of EGFR-ALK cases harbored the EML4-ALKV3. Non-smokers exhibited superior overall survival (OS) in both cases (internal p = 0.002, external pooled cases p = 0.03). Among 10 advanced-stage patients with sufficient clinical follow-up, two had received dual-targeted TKI therapies. Both patients tolerated dual-targeted TKI therapies well, with one requiring dose adjustment due to initial toxicity and subsequently achieving an overall survival exceeding 51 months; however, limited sample size precludes definitive conclusions regarding efficacy.
conclusionDe novo co-mutations represent a distinct NSCLC subset with unique clinical and genomic features, and dual-targeted therapy shows promise as a strategy that warrants evaluation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.